Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 12:14:1258991.
doi: 10.3389/fonc.2024.1258991. eCollection 2024.

Cardiovascular disease and lung cancer

Mikhail de Jesus  1 , Anindita Chanda  2 , Titas Grabauskas  3 , Manish Kumar  4 , Agnes S Kim  4
Affiliations
Review

Cardiovascular disease and lung cancer

Mikhail de Jesus et al. Front Oncol. .

Abstract

Lung cancer is the second most common cancer worldwide and the leading cause of cancer-related death. While survival rates have improved with advancements in cancer therapeutics, additional health challenges have surfaced. Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in patients with lung cancer. CVD and lung cancer share many risk factors, such as smoking, hypertension, diabetes, advanced age, and obesity. Optimal management of this patient population requires a full understanding of the potential cardiovascular (CV) complications of lung cancer treatment. This review outlines the common shared risk factors, the spectrum of cardiotoxicities associated with lung cancer therapeutics, and prevention and management of short- and long-term CVD in patients with non-small cell (NSCLC) and small cell (SCLC) lung cancer. Due to the medical complexity of these patients, multidisciplinary collaborative care among oncologists, cardiologists, primary care physicians, and other providers is essential.

Keywords: cardiac adverse events; cardiotoxicities; chemotherapy; immunotherapy; lung cancer; non-small cell lung cancer; small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Jemal A, Siegel R, Kratzer TB. Cancer statistics center. Am Cancer Soc. doi: 10.3322/caac.21763 - DOI
    1. U.S. Cancer Statistics Working Group . U.S. Cancer Statistics Data Visualizations Tool, based on 2021 submission data (1999-2019). U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; (2022). Available at: https://www.cdc.gov/cancer/dataviz.
    1. Surveillance, Epidemiology, and End Results (SEER) Program . SEER*Stat Database: Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent) By Primary Cancer Site, Sex and Time Period, National Cancer Institute, DCCPS, Surveillance Research Program.
    1. Sun JY, Zhang ZY, Qu Q, Wang N, Zhang YM, Miao LF, et al. . Cardiovascular disease-specific mortality in 270,618 patients with non-small cell lung cancer. Int J Cardiol (2021) 330:186–93. doi: 10.1016/j.ijcard.2021.02.025 - DOI - PubMed

LinkOut - more resources